ArticleScientific reports2025
B-vac a robust software package for bacterial vaccine design.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Reverse Vaccinology (RV) has revolutionized vaccine discovery, utilizing bioinformatics to surpass traditional methods in identifying genes and proteins. By analyzing pathogen genomic data, RV pinpoints proteins with key traits such as immunogenicity, surface localization, and conservation across strains. Despite its advantages, current RV tools face challenges like prediction accuracy, computational demands, and accessibility. To address these challenges, we introduce B-vac, an executable pipeline designed to streamline bacterial vaccine design. B-vac features a user-friendly interface and robust algorithms for high-throughput proteomics data analysis, covering modules like Localization, Non-host Homolog, Virulence Factor, and Epitope Mapping. It operates offline, enhancing accessibility for researchers with limited computational resources. B-vac is equipped with epitope libraries, bacterial proteomes and virulence factor database which helps the program process the protein sequences locally and feeds data back to users with the ability to set variables and toggles for cut-off and filter values. The B-vac pipeline uses a string-based matching approach to match proteomes supplied by users with the pipeline's curated database. This approach aligns and compares pathogen protein sequences by string similarity and enables the researchers to easily identify motifs important for immunogenic function. Evaluation of the pipeline by employing the Helicobacter pylori proteome revealed B-vac's effectiveness in identifying vaccine candidates. B-vac offers a user-friendly, standalone solution for bacterial vaccine development, eliminating the need for external libraries and enabling offline usability, addressing key gaps in convenience and accessibility compared to existing RV tools. B-vac can be downloaded from: https://mgbio.tech/tools/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.